MedTrace Logo

Retrospective Transverse Observational Study Of Previous Study (Initial Protocol, B1811030)

NCT01840319 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 156

Last updated 2014-07-28

Study results available
· View outcomes & findings →

Summary

The goal of this retrospective observational study is to collect only status survival data 30 days after the last dose of treatment of patients included in the initial protocol WYETH 3074A1-4448 / B1811030. The purpose is to estimate the survival status, 30 days after the last intake of tigecycline to patients hospitalized in ICU and treated by tigecycline.

Conditions

  • Survival Status at Day 30 After the Last Intake

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01840319 on ClinicalTrials.gov